STOCK TITAN

Oculis Holding (OCS) Financials

OCS NASDAQ
FY2025 annual
Revenue $1.5M +99.7% YoY
Net Income -$124.7M n/m YoY
EPS (Diluted) -$2.38 n/m YoY
Free Cash Flow -$83.9M n/m YoY
Market Cap $508.7M as of Oct 30, 2026
Price / Sales 337x on $1.5M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 2.1x on $247.1M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OCS SEC filings page.

Oculis Holding AG (OCS) reported $1.5M in revenue for fiscal year 2025, up 99.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Financial Health Signals

Financial health score not available

Oculis Holding AG does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe
3.58

Oculis Holding AG scores 3.58, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $508.7M against total liabilities of $50.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/6

Oculis Holding AG passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Oculis Holding AG reported a net loss of $124.7M while operations used $83.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Oculis Holding AG reported an operating loss of $102.9M against $1.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.5M
YoY+99.7%
5Y CAGR+6.1%

Oculis Holding AG generated $1.5M in revenue in fiscal year 2025. This represents an increase of 99.7% from the prior year.

Net Income
-$124.7M
YoYn/m
5Y CAGRn/m

Oculis Holding AG reported a net loss of $124.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$2.38
YoYn/m

Oculis Holding AG earned -$2.38 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$83.9M
YoYn/m
5Y CAGRn/m

Oculis Holding AG recorded an outflow of $83.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$102.5M
YoY+235.4%
5Y CAGR+78.8%

Oculis Holding AG held $102.5M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
Diluted avg 52M

Oculis Holding AG had a weighted average of 52M diluted shares in fiscal year 2025; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-50.5%
YoY+66.4pp

Oculis Holding AG's ROE was -50.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 66.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$71.9M
YoY+25.2%
5Y CAGR+46.8%

Oculis Holding AG invested $71.9M in research and development in fiscal year 2025. This represents an increase of 25.2% from the prior year.

Capital Expenditures
$379K
YoY+49.5%
5Y CAGR+77.6%

Oculis Holding AG invested $379K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 49.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

OCS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCS annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-F
Revenue$1.5M+99.7%$757K-28.0%$1.1M+6.5%$987K-6.0%$1.0M-6.5%$1.1M
R&D Expenses$71.9M+25.2%$57.4M+65.1%$34.8M+44.7%$24.0M+129.9%$10.5M-0.9%$10.6M
Operating Income-$102.9Mn/m-$80.7Mn/m-$96.0Mn/m-$35.0Mn/m-$14.5Mn/m-$14.0M
Interest Expense$1.0M+49.0%$705K-55.0%$1.6M+2577.4%$58K-28.7%$82K+302.8%$20K
Income Tax-$234Kn/m-$176K-238.6%$127K+113.9%$60K+101.6%$30K-68.6%$94K
Net Income-$124.7Mn/m-$94.6Mn/m-$105.7Mn/m-$41.9Mn/m-$20.3Mn/m-$16.8M
EPS (Basic)-$2.38n/m-$2.34n/m-$3.53-$12.25n/m-$6.39n/m-$6.53
EPS (Diluted)-$2.38n/m-$2.34n/m-$3.53-$12.25n/m-$6.39n/m-$6.53
Diluted Shares (Avg)52M+29.3%40M+35.1%30M3M+7.6%3M+7.7%3M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA.

OCS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCS annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-F
Total Assets$297.3M+124.0%$132.7M-2.4%$136.1M+239.3%$40.1M-36.8%$63.5MN/A
Current Assets$275.8M+138.4%$115.7M-3.7%$120.2M+369.5%$25.6M-51.2%$52.5MN/A
Cash & Equivalents$102.5M+235.4%$30.6M-33.0%$45.6M+113.0%$21.4M-57.7%$50.6M+803.3%$5.6M
Total Liabilities$50.3M-3.0%$51.8M+111.1%$24.5M-83.2%$146.1M+12.3%$130.1MN/A
Current Liabilities$46.3M-5.1%$48.8M+114.8%$22.7M+74.6%$13.0M+192.9%$4.4MN/A
Non-Current Liabilities$4.0M+31.4%$3.0M+64.9%$1.8M-98.6%$133.1M+5.9%$125.7MN/A
Total Equity$247.1M+205.3%$80.9M-27.4%$111.5Mn/m-$106.0Mn/m-$66.6Mn/m-$49.4M
Retained Earnings-$484.5Mn/m-$314.9Mn/m-$237.7Mn/m-$120.1Mn/m-$79.0MN/A

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

OCS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCS annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-F
Operating Cash Flow-$83.5Mn/m-$53.9Mn/m-$65.5Mn/m-$27.1Mn/m-$15.1Mn/m-$13.6M
Capital Expenditures$379K+49.5%$254K+344.1%$57K-18.8%$70K+129.8%$31K+42.5%$21K
Free Cash Flow-$83.9Mn/m-$54.2Mn/m-$65.5Mn/m-$27.2Mn/m-$15.1Mn/m-$13.6M
Investing Cash Flow-$76.8Mn/m-$17.7Mn/m-$63.0Mn/m-$3.8Mn/m-$31Kn/m-$21K
Financing Cash Flow$235.5M+295.7%$59.5M-61.4%$154.2M+8215.0%$1.9M-96.9%$60.3M+998.0%$5.5M

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.

OCS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCS annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-F
Operating Margin-6811.7%-10671.1%-9140.9%-3550.0%-1378.3%-1242.3%
Net Margin-8253.3%-12503.9%-10056.9%-4243.2%-1932.5%-1497.8%
Return on Equity-50.5%+66.4pp-116.9%-22.2pp-94.7%N/AN/AN/A
Return on Assets-41.9%+29.3pp-71.3%+6.4pp-77.7%+26.8pp-104.4%-72.5pp-32.0%N/A
Current Ratio5.96+3.6x2.37-2.9x5.29+3.3x1.97-9.8x11.81N/A
Liabilities-to-Equity0.20-0.4x0.64+0.4x0.22N/AN/AN/A
Asset Turnover0.010.0x0.010.0x0.010.0x0.020.0x0.02N/A
FCF Margin-5555.0%-7164.6%-6238.4%-2756.5%-1443.0%-1213.3%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Oculis Holding AG OCS FY2025 $1.5M -$124.7M N/A $508.7M —
Arbutus Biopharma Corporation ABUS FY2025 $14.1M -$33.5M N/A $847.9M 64/100
uniQure N.V. QURE FY2025 $16.1M -$199.0M N/A $1.8B 57/100
EyePoint, Inc. EYPT FY2025 $31.4M -$232.0M N/A $32.8M 55/100
Taysha Gene Therapies, Inc. TSHA FY2025 $9.8M -$109.0M N/A $1.4B 55/100
Upstream Bio, Inc. UPB FY2025 $2.9M -$143.4M N/A $179.1M 55/100

Frequently Asked Questions

What is Oculis Holding AG's annual revenue?

Oculis Holding AG (OCS) reported $1.5M in total revenue for fiscal year 2025. This represents a 99.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Oculis Holding AG's revenue growing?

Oculis Holding AG (OCS) revenue grew by 99.7% year-over-year, from $757K to $1.5M in fiscal year 2025.

Is Oculis Holding AG profitable?

No, Oculis Holding AG (OCS) reported a net loss of $124.7M in fiscal year 2025.

Oculis Holding AG (OCS) reported diluted earnings per share of -$2.38 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oculis Holding AG (OCS) has a return on equity of -50.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Oculis Holding AG (OCS) recorded an outflow of $83.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Oculis Holding AG (OCS) recorded an outflow of $83.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Oculis Holding AG (OCS) had $297.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Oculis Holding AG (OCS) invested $379K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Oculis Holding AG (OCS) invested $71.9M in research and development during fiscal year 2025.

Oculis Holding AG (OCS) had a current ratio of 5.96 as of fiscal year 2025, which is generally considered healthy.

Oculis Holding AG (OCS) had a liabilities-to-equity ratio of 0.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Oculis Holding AG (OCS) had a return on assets of -41.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Oculis Holding AG (OCS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $508.7M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Oculis Holding AG (OCS) trades at 337x sales, its market capitalization divided by $1.5M revenue, FY2025. The market capitalization is $508.7M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Oculis Holding AG (OCS) has an Altman Z-Score of 3.58, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Oculis Holding AG (OCS) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Oculis Holding AG (OCS) reported a net loss of $124.7M while operations used $83.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Oculis Holding AG (OCS) reported an operating loss of $102.9M against $1.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top